drugset / Trial / NCT06384235
Phase II Clinical Study of LTC004 in Patients With mCRC
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase II clinical study to evaluate the safety and antitumor activity of LTC004 in patients with locally advanced or metastatic CRC，Enrollment of 10 evaluable subjects in Phase I. If ≥2 subjects experience objective remission，proceed to Phase II to enroll an additional 20 evaluable subjects to further evaluation of the safety and efficacy of LTC004
Timeline
- Start
- 2024-04-25
- Primary completion
- 2025-08-23
- Completion
- 2025-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LTC004 | Unknown | 45 ug/kg | Intravenous |